← Shanghai Haoyuan Chemexpress Co. Ltd. A overview

Shanghai Haoyuan Chemexpress Co. Ltd. A vs Charles River Laboratories: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Haoyuan Chemexpress Co. Ltd. A (688131.CG)

Q3 2026
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

August 2026
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Latest
▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

  • FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.

    A concrete regulatory milestone that expands the addressable market and supports future earnings.

  • First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.

    The half-year results are the clearest evidence of the company's underlying earnings trend.

  • Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.

    Dividend policy is a direct signal of financial health and shareholder returns.

  • 15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.

    Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Charles River Laboratories (CRL)

Q3 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

July 2026
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Latest
▲4

CRL's biotech recovery and AI deals drive 89% rally

  • AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.

    New collaboration that expands demand and technology positioning, directly driving future revenue.

  • Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.

    Analyst upgrade reflects improving fundamentals and boosts investor sentiment.

  • Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.

    Earnings beat and guidance raise confirm operational turnaround, a key price driver.

  • DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.

    Summarizes the powerful rally and underlying operational improvements that continue to support the stock.